What cases are to be reported?

Reportable Diagnoses

The Louisiana Tumor Registry requires that ALL in situ and invasive neoplasms (cancers with behavior codes 2 or 3 as listed in the current ICD-O manual) be reported. NOTE: Certain histologies containing previously non-reportable terms such as neoplasm, tumor, dysplasia, -oma etc may NOW be reportable thus always verify behavior using ICD-O!

Effective January 1, 2023, the following are reportable:

  • Squamous Intraepithelial Neoplasias, grade II (SIN II)
  • High grade astrocytoma with piloid features (HGAP) (9421/3)
  • Mesothelioma in situ (9050/2)
  • Diffuse leptomeningeal glioneuronal tumor (9509/3)
  • Lymphangioleiomyomatosis (9174/3); behavior changed from /1 to /3

Effective January 1, 2022, the following are reportable:

  • Clear cell papillary renal cell carcinoma (8323/3) is to be REPORTED w/ BEHAVIOR 3 until further notice
  • Intraductal oncocytic papillary neoplasm, NOS (8455/2)
  • Intraductal oncocytic papillary neoplasm with associated invasive carcinoma (8455/3)
  • Chondrosarcoma, grade 1 (9222/3), behavior changed from /1 to /3
  • The following 8480 APPENDICEAL histologies are reportable:
    • Low-grade appendiceal mucinous neoplasm (LAMN) 8480 now has behavior /2 or /3):
      • /2 = Tis (LAMN) confined by muscularis propria (T1-T2 are not used for LAMN)
      • /3 = T3-T4 extending into subserosa or serosa
    • High grade appendiceal mucinous neoplasm (HAMN) (8480/2)
    • Appendiceal mucinous neoplasm w/ extra-appendiceal spread (8480/3)
  • The following histologies are reportable ONLY for STOMACH & SMALL INTESTINE (C16.0 – C16.9, C17.0 -C17.9):
    • Intestinal-type adenoma, high grade
    • Serrated dysplasia, high grade

Effective January 1, 2021, the following are reportable:

  • Early or evolving melanoma, in situ AND invasive
  • High grade squamous dysplasia of the TONGUE (8077/2)
  • All GIST tumors, EXCEPT for those stated to be benign
    • Prior to 2021, GIST NOS were only reportable when there was evidence of multiple foci, lymph node involvement or metastasis)
  • Nearly all thymomas EXCEPT for the following:
    • Microscopic thymoma or thymoma, benign (8580/0)
      • Micronodular thymoma with lymphoid stroma (8580/1)
      • Ectopic hamartomatous thymoma (8587/0)
      • NOTE: Prior to 2021, thymomas were only reportable when there was evidence of multiple foci, lymph node involvement or metastasis
    • Endometrial intraepithelial neoplasia/ Atypical hyperplasia of the endometrium (EIN/AH–8380/2)
    • ACTH-producing tumor (8158/3)
    • Aggressive digital papillary adenoma (C44. _ ; 8408/3), behavior changed from /1 to /3

Carcinoid, NOS of the appendix is reportable, effective January 1, 2015, forward
Please note: the ICD-O behavior code has changed from /1 to /3.

All Squamous Intraepithelial Neoplasias, grade II (effective January 1, 2023) AND grade III (SIN II AND SIN III) as well as Intraepithelial Neoplasias NOS stated to be high grade, grade II (effective January 1, 2023) or grade III are reportable, including (but not limited to):  [excluding skin sites coded to C44_]

  • Anal Intraepithelial Neoplasia (AIN II, effective 1/1/23 & AIN III–C21.0-C21.1)
    • Exception: AIN II or AIN III (8077) arising in perianal skin (C445) is non-reportable
  • Biliary intraepithelial neoplasia, high grade (BiIN III-C23.9), effective January 1, 2018 forward
  • Cervical intraepithelial neoplasia (CIN II, effective 1/1/23 & CIN III–C53.0-C53.9, effective January 1, 2009 forward).  Please see CIN III Reporting Details
  • Conjunctival intraepithelial neoplasia/lesion (CIN III-C69.0)
  • Endometrioid intraepithelial neoplasia/ Atypical hyperplasia of the endometrium (EIN/AH–8380/2)
  • Esophageal intraepithelial neoplasia (dysplasia), high grade
  • Glandular intraepithelial neoplasia, high grade
  • Intraductal papillary neoplasm with high grade intraepithelial neoplasia
  • Intraepithelial neoplasia, grade II, grade III or high grade
  • Laryngeal Intraepithelial neoplasia (LIN II, effective 1/1/23 & LIN III—C32.0-C32.9)
  • Lobular Neoplasia, grade II (LN II, effective 1/1/23)  & grade III (LN III, effective 1/1/2016 forward) breast—C500-C509
  • Lobular Intraepithelial neoplasia, grade II (LIN II, effective 1/1/23) & grade III (LIN III, effective 1/1/2016 forward) breast—C500-C509
  • Pancreatic intraepithelial neoplasia (PanIN II, effective 1/1/2023 & PanIN III, effective 1/1/2018 forward—-C250-C259)
  • Penile Intraepithelial neoplasia, grade II (PeIN II, effective 1/1/2023) & grade III (PeIN III, effective 1/1/2016 forward—C600-C609)
  • Vaginal intra-epithelial neoplasia (VAIN II, effective 1/1/2023 & VAIN III—C52.9)
  • Vulvar intraepithelial neoplasia (VIN II, effective 1/1/2023 & VIN III—C51.0-C51.9)
  • Differentiated vulvar intraepithelial neoplasia (VIN)


Carcinoma in situ (CIS) of the cervix –effective January 1, 2009 forward as well as Adenocarcinoma in situ, HPV-associated (8483/2) AND HPV-independent, NOS of the cervix (8484/2)—effective January 1, 2022. Please see CIN III Reporting Details

Lobular carcinoma in situ (LCIS) of the breast REMAINS REPORTABLE to the LTR

Effective January 1, 2016 the following PANCREATIC histologies are reportable:

  • Non-invasive mucinous cystic neoplasm (MCN) of the pancreas with high grade dysplasia replaces the term mucinous cystadenocarcinoma, non-invasive and is reportable as 8470/2
  • Solid pseudopapillary neoplasm of pancreas is synonymous with solid pseudopapillary carcinoma (C25._) and is reportable as 8452/3
  • Cystic Pancreatic Endocrine Neoplasms (CPENs) will be considered malignant, until proven otherwise:
    • Most CPENs are reportable as 8150/3, UNLESS the tumor is specified as a neuroendocrine tumor either grade 1 or 2
      • neuroendocrine tumor, grade 1 (assign code 8240/3) OR
      • neuroendocrine tumor, grade 2 (assign code 8249/3)


Noninvasive low grade (micropapillary) serous carcinoma (MPSC) of the ovary is reportable as 8460/2

Mature teratoma of the testes in ADULTS is malignant and reportable as 9080/3 but continues to be non-reportable in prepubescent children (9080/0).

American College of Radiology Reporting and Data Systems (RADS) Reportability Effective January 1, 2018, the following cancer cases are reportable unless there is info to the contrary:

  • Liver cases with an LI-RADS category LR-4 (effective 1/1/21), LR-5 or LR-5V
  • Prostate cases with a PI- RADScategory 4 or 5

All tumors of the brain and central nervous system (site codes C70.0-C72.9 and C75.1-C75.3 in ICD-O) are to be reported, regardless of behavior code.

  • Benign brain and CNS tumors are reportable effective January 1, 2004
    • Neoplasm and tumor ARE REPORTABLE terms for intracranial and CNS because they are listed in ICD-O with behavior codes of /0 and /1
    • MASS and LESION are NON reportable terms for intracranial and CNS because they are NOT listed in ICD-O with behavior codes of /0 or /1
  • Juvenile/pilocytic astrocytomas
    • Cases diagnosed PRIOR to 01/01/2023 should be reported as 9421/3 when the primary site is C71._ NOTE: Behavior is non-malignant when the primary site is optic nerve (C72.3).
    • Cases diagnosed AFTER 01/01/2023 should be reported as 9421/1 for ALL CNS sites
  • Effective January 1, 2023 report the following w/ the corresponding M-code:
    • Diffuse astrocytoma, MYB- OR MYBL1-altered (9421/1)
    • Diffuse low-grade glioma, MAPK pathway-altered (9421/1)
    • Multinodular AND vacuolating neuronal tumor (9509/0)
    • Juvenile xanthogranuloma (9749/1) —C715 is the most common site

Positive urine cytologies: Effective 2013, these should be reported if they document the presence of “positive malignant cells” or “(malignant) cells interpreted as carcinoma” and should be coded to C68.9 Urinary System NOS in the absence of any other information on the site of origin.

Two exceptions to the instructions about reporting positive urine cytologies:

  1. If the positive urine cytology is later followed by a negative tissue biopsyof a urinary site, DO NOT REPORT, as the pathology proved the cytology to be incorrect. The pathologic diagnosis is the “gold standard.” When cytology and pathology disagree, always use the pathology. (SEER SINQ 20100106 & 20120079)
  2. Urine cytologies utilizing ambiguous terminologyare not reportable.For example, do not report a urine cytology that is “suspicious for malignant cells.”

Non-reportable Diagnoses

The following are not reportable:

  • Prostatic intraepithelial neoplasia, grade III (PIN III—after 1/1/2001)
  • Squamous intraepithelial neoplasia of the cervix (CIN III—effective 1996-2008 only)
  • Colon atypical hyperplasia
  • High grade dysplasia OR Intraepithelial neoplasia, high grade ONLY in COLORECTAL primary sites
  • Certain Hematopoietic Diseases–there are several Hematopoietic diseases that are similar to reportable Hematopoietic neoplasms. Refer to the SEER Hematopoietic and Lymphoid Neoplasm Database to determine reportability
  • Skin cancers (C44._ range only) with histologies 8000-8005, 8010-8046, 8050-8084, and 8090-8110. These include, but are not limited to, basal cell and squamous cell carcinomas, as well as, squamous intraepithelial neoplasia III (SIN III) (8077) of skin sites coded to C44._

Note 1: All skin cancers (C44._ range) with histologies other than those listed above must be reported.

Note 2: Skin cancers, regardless of histology, must be reported if they are NOT in the C44._ range. This includes the following:

  • Skin of the labia majoria, C51.0
  • Skin of the penis C60.9
  • Skin of the scrotum C63.2
  • Skin of the vulva C51.9

Additional Reporting References

Additional Reporting Clarifications

The Resourceful Registrar section of this website includes many reporting and coding clarifications, as well as, manual references for abstracting cancer cases.